Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study

Author:

Ryan Pablo1234ORCID,Valencia Jorge512,Cuevas Guillermo2,Amigot-Sanchez Rafael61,Martínez Isidoro61ORCID,Lazarus Jeffrey V78,Pérez-García Felipe1910ORCID,Resino Salvador61ORCID

Affiliation:

1. Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain

2. Hospital Universitario Infanta Leonor, Madrid, Spain

3. Universidad Complutense de Madrid (UCM), Madrid, Spain

4. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

5. Unidad de Reducción de Daños ‘SMASD’, Madrid, Spain

6. Unidad de Infección e Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

7. CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, United States

8. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain

9. Servicio de Microbiología Clínica, Hospital Universitario Príncipe de Asturias, Madrid, Spain

10. Universidad de Alcalá, Facultad de Medicina, Departamento de Biomedicina y Biotecnología, Madrid, Spain

Abstract

Background People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors. Results Of all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p < 0.001 for all). These downward trends were confirmed by adjusted logistic regression for the entire study population (adjusted odds ratio (aOR): 0.78), PWID (aOR: 0.78), and PWUD non-IDU (aOR: 0.78). Conclusions Our study demonstrates a significant reduction in active HCV infection prevalence among PWUD, particularly in PWID, which suggests that efforts in the prevention and treatment of HCV in Madrid, Spain, have had an impact on the control of HCV infection.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference42 articles.

1. World Health Organization (WHO). Hepatitis C, 2024. Geneva: WHO; 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c

2. Hepatitis C.;Spearman;Lancet,2019

3. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.;Blach;Lancet Gastroenterol Hepatol,2022

4. 2º Estudio de Seroprevalencia en España, 2017-2018 [2nd Seroprevalence Study in Spain, 2017-2018];Limia Sánchez;Rev Esp Salud Publica,2021

5. Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.;Bhattacharya;Clin Infect Dis,2023

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3